BOYER ANDREW S 4

4 · Amneal Pharmaceuticals, Inc. · Filed Mar 5, 2026

Insider Transaction Report

Form 4

Period: 2026-03-03

Amneal Pharmaceuticals, Inc.AMRX

BOYER ANDREW S

Executive Vice President

Transactions

Exercise/Conversion
Class A Common Stock
[F1][F2]
2026-03-03+39,252→ 191,678 total
Tax Payment
Class A Common Stock
[F3]
2026-03-03$13.31/sh−19,945$265,468→ 171,733 total
Exercise/Conversion
Class A Common Stock
[F1][F2]
2026-03-03+49,694→ 221,427 total
Tax Payment
Class A Common Stock
[F3]
2026-03-03$13.31/sh−24,897$331,379→ 196,530 total
Exercise/Conversion
Class A Common Stock
[F1][F2]
2026-03-03+24,258→ 220,788 total
Tax Payment
Class A Common Stock
[F3]
2026-03-03$13.31/sh−12,154$161,770→ 208,634 total
Exercise/Conversion
Class A Common Stock
[F4]
2026-03-03+397,554→ 606,188 total
Tax Payment
Class A Common Stock
[F5]
2026-03-03$13.31/sh−199,175$2,651,019→ 407,013 total
Exercise/Conversion
Class A Common Stock
[F1][F2]
2026-03-04+38,195→ 445,208 total
Tax Payment
Class A Common Stock
[F3]
2026-03-04$13.30/sh−19,136$254,509→ 426,072 total
Exercise/Conversion
Restricted Stock Units
[F2][F6]
2026-03-03−39,252→ 0 total
→ Class A Common Stock (39,252 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F7]
2026-03-03−49,694→ 49,695 total
→ Class A Common Stock (49,694 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F8]
2026-03-03−24,258→ 72,774 total
→ Class A Common Stock (24,258 underlying)
Exercise/Conversion
Performance-Based Restricted Stock Units
[F4]
2026-03-03−397,554→ 0 total
→ Class A Common Stock (397,554 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F9]
2026-03-04−38,195→ 76,389 total
→ Class A Common Stock (38,195 underlying)

Footnotes (9)

[F1]Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
[F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
[F3]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
[F4]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.
[F5]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.
[F6]On March 4, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
[F7]On March 3, 2023, the reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
[F8]On March 3, 2025, the reporting person was granted 97,032 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
[F9]On March 4, 2024, the reporting person was granted 152,778 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Signature

/s/ Denis Butkovic, Attorney-in-Fact|2026-03-05

Documents

1 file

4
wk-form4_1772746263.xmlPrimary
FORM 4